From the initial stages of compound screening to the detailed analysis of drug efficacy and safety, our IVP services integrate seamlessly into the drug development pipeline. Our sophisticated CDX (Cell-Derived Xenograft) models, which include living image cell lines, drug-resistant variants, and gene-edited lines, are meticulously designed to reflect the human biological response to novel treatments. These models serve as critical platforms for testing and refining anti-tumor agents, ensuring that only the most promising candidates move forward in the drug discovery process.
ICE Bioscience provides end-to-end biomarker discovery and detection services designed to accelerate drug development and enhance therapeutic decision-making. From sample collection and processing to biomarker validation and quantification, our advanced platforms and scientific expertise ensure the accurate identification of critical biomarkers. Whether you're in early-stage discovery or clinical development, our services support robust, data-driven insights for drug efficacy, safety assessment, and patient stratification.
Cardiac safety assessment is a critical component of the drug development process, aimed at identifying potential adverse effects of pharmaceutical compounds on the heart. The significance of these evaluations lies in their capacity to prevent drug-induced cardiac arrhythmias, which can lead to serious health outcomes, including sudden cardiac death. By systematically identifying and mitigating these risks early in drug development, cardiac safety assessments protect patient health and contribute to the development of safer therapeutic options.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
